DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for lipoma — screening already-approved drugs against its 31-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLipoma maps to a 31-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for lipoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
A 2013 study treated twelve lipomas in nine patients with high-intensity focused ultrasound (HIFU) over four sessions at three-week intervals. Lipoma volume before treatment ranged from 2.7 to 169.4 cm³; after treatment the range was 0.2 to 119.8 cm³. Mean volume reduction was 58.1 ± 22.8%. The average pain score on a standard visual analogue scale was 4.1 ± 2.4. No significant adverse effects were reported. The authors concluded the treatment was safe and well-tolerated, and that HIFU might be an alternative when surgery is undesirable or ineffective.
A 2015 study compared cells from lipoma tissue with cells from normal adipose tissue. CD34-positive cells were found around small adipocytes in lipomas, and these cells showed altered proliferation, apoptosis, and stemness activity. The authors suggested that cell precursors may be involved in lipoma development but stated this hypothesis requires further investigation.
A 2017 study examined thirty patients after lipoma excision: twenty had encapsulated lipomas and ten had non-encapsulated lipomas. Non-encapsulated lipomas were associated with older age at operation, larger tumour size, and increased seroma formation. They also showed higher density of lymphatic vessels and increased gene expression related to lymphatic vessels, inflammation, and proliferation. Adipose-derived stem cells from non-encapsulated lipomas showed enhanced proliferation when cultured with serum.
No drug treatment for lipoma is described in any of these abstracts. What remains missing is any pharmacological intervention tested in a controlled trial, any molecular target validated in patients, and any stratification of lipoma subtypes that might predict response to a drug.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Biological Sciences · 2015 · 23 citations · open access
Persistence of CD34 Stem Marker in Human Lipoma: Searching for Cancer Stem Cells
AbstractBACKGROUND: Lipomas are benign solid tumours that develop in soft tissues with origin in mesenchymal progenitors. Macroscopically, they appear as soft-elastic nodules, varying in volume from a few millimiters to several centimetres and can enlarge progressively. Although they are usually asymptomatic, they can cause symptoms due to nerve or vessel compression. Microscopically they appear as fibrous connective tissue stroma with embedded adipocytes, and absence of inflammation. Up to now no characterisation of stem cell population present in this tissue has been performed. METHODS: Cytofluorimetric, biological and molecular biology analyses have been performed in order to test superficial cell markers and gene expression profile related to stemness and apoptotic activity of cells present in lipoma tissues compared to those of adipose tissue's cells. RESULTS: Our results confirmed that CD34(+) cells in lipoma were present around small adipocytes, showing several altered biological activity such as proliferation, apoptotis and stemness. CONCLUSIONS: The data emerging from the comparison of the lipoma cells and normal adipose tissue, suggests the presence of cell precursors involved in the development of the lipoma. This hypothesis requires further investigation and may indicate new thresholds in the study of benign tumour pathogenesis.
Noninvasive Lipoma Size Reduction Using High-Intensity Focused Ultrasound
AbstractBACKGROUND: Lipomas are common benign mesenchymal tumors commonly removed using excision, but in certain cases, surgery is undesirable or ineffective. High-intensity focused ultrasound (HIFU) offers a noninvasive tumor ablation tool increasingly used in the clinic. OBJECTIVE: To evaluate the efficacy and safety of a noninvasive lipoma size reduction technology using HIFU. MATERIALS & METHODS: Twelve lipomas in nine patients were treated. Patients underwent four treatment sessions with a 3-week interval between treatments. Blood and urine tests and tolerability based on a standard visual analogue scale (VAS) were used to monitor patients for adverse effects. Lipoma volume was determined by measuring width and length (manually) and depth (ultrasonically). RESULTS: The range of lipoma size was 2.7-169.4 cm3 before treatment and 0.2-119.8 cm3 after treatment. Mean volume reduction was 58.1 ± 22.8%. When palpated, the lipomas felt much softer than before treatment. The average VAS score was 4.1 ± 2.4. No significant adverse effects were noted. CONCLUSION: The treatment was shown to be effective in noninvasively reducing lipoma size. The average volume reduction was substantial and statistically significant. The treatment was safe and well-tolerated. HIFU may be an alternative treatment modality in cases of lipoma.
Journal of Plastic Surgery and Hand Surgery · 2017 · 10 citations · open access
Characterization of two distinct lipomas: a comparative analysis from surgical perspective
AbstractBACKGROUND: Lipomas are common benign soft tissue tumors that are well-circumscribed and encapsulated. However, adipose masses that are not demarcated from the surrounding fat are often encountered. Two distinct types of lipomas were analyzed from surgical perspective. METHODS: Thirty patients were enrolled after lipoma excision and diagnosed with either encapsulated (n = 20) or non-encapsulated lipoma (n = 10). Comparison of clinical variables, histologic analyses and characterization of the lipoma adipose-derived stem cells (ASCs) between the two lipomas were performed. RESULTS: Non-encapsulated lipomas were associated with older age at operation, larger tumor and increased seroma formation. The density of lymphatic vessels and gene expressions related to lymphatic vessel, inflammation and proliferation were increased in non-encapsulated lipoma. ASCs of non-encapsulated lipoma showed enhanced proliferation when cultured with serum. CONCLUSIONS: Non-encapsulated lipomas and their ASCs showed distinct lymphatic histology and cellular response. These findings elucidated the pathogenesis and pathophysiology of lipomas.
Journal of Cosmetic and Laser Therapy · 2011 · 6 citations
Recurrent growth of lipomas after previous treatment with phosphatidylcholine and deoxycholate
AbstractInjections with phosphatidylcholine- and deoxycholate-containing substances are used to reduce localized fat accumulations. Recent studies have suggested that this procedure may be a non-surgical alternative for reducing the size of lipomas. However, only short-term data about efficacy are available, and it is unclear whether a permanent reduction in lipoma size is possible. In the present case we report a patient who presented with recurrent growth lipomas that were previously successfully treated using phosphatidylcholine and deoxycholate.
Journal of Pharmacy And Bioallied Sciences · 2024 · 1 citations · open access
Lipoma in the Oral Cavity: A Rare Entity
AbstractLipoma is a painless soft tissue tumor of mesenchymal origin, which is a well-defined and slow-growing tissue. The occurrence of lipoma is rare in the oral cavity (1-4%); however, the frequency is much higher in the head and neck region. The lipoma is commonly present in the buccal mucosa, lips, tongue, palate, buccal sulcus, and floor of the mouth. Sometimes, the lipoma becomes large enough to cause difficulty in speech and mastication. The main treatment for lipoma is surgical excision.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
